Bristol Myers Squibb Company
NEWS
Now that Bristol-Myers Squibb is acquiring Celgene, the company will largely disappear into Bristol-Myers Squibb, but a legacy of bold risk-taking and questionable price hikes remain.
Nonalcoholic steatohepatitis (NASH) is prevalent in the U.S. and developing countries, but under that name, is largely unknown to the general public. NASH is a liver disease similar to cirrhosis, but which occurs in people who drink little or no alcohol.
Ahead of being absorbed by Bristol-Myers Squibb, Celgene forged a strategic collaboration with two companies to develop immuno-oncology treatments and cell therapies.
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
Federal corporate tax cuts that were framed as a way to give a boost to employment across the United States have been more beneficial to companies and shareholders than the average worker or consumer, a new report issued by the advocacy group Americans for Tax Fairness shows.
It’s a new year! Is one of your New Year’s resolutions to find a new job? Jump start your job search now and check out top companies who are looking for quality candidates in 2019!
Over the past decade, BMS has been no stranger to flexing its M&A muscle. The company made numerous focused-acquisitions that have positioned itself as a leader in oncology. BMS CEO Giovanni Caforio noted that the massive deal for Celgene is another piece to that puzzle.
Bristol-Myers Squibb will acquire Celgene Corporation to create a pharma giant with a significant pipeline focused on oncology, inflammatory and immunologic diseases, and cardiovascular disease.
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.
JOBS
IN THE PRESS